Klinea BioPharmaceutical Engineering is #Biotech
Klinea, part of an innovation ecosystem in Advanced Therapies.
Biocat has selected Klinea BioPharmaceutical Engineering to be part of the prestigious Advanced Therapies Network of Catalonia, an initiative promoted by the Government of Catalonia to accelerate the development and access of these therapies to patients. As one of the 45 companies and organizations selected for this initiative, Klinea joins an ecosystem with great potential in the field of advanced treatments, which seeks to consolidate the BioRegion of Catalonia as a world reference in this field.
Catalonia has positioned itself as an outstanding leader in advanced therapies. The region leads the national ranking in scientific publications, with 2,195 publications, representing 38% of the national total. At the European and international level, Catalonia is a benchmark in the participation of clinical trials in advanced therapies, ranking fifth in Europe and eighth worldwide. Moreover, Catalonia has received 64% of the total funding of the CERTERA call, consolidating its leadership in developing these therapies in Spain.
The Advanced Therapies Network addresses key challenges such as training and retention of talent, technology transfer, project acceleration, scale-up of therapies and market access. In addition, it fosters public-private collaboration and the strengthening of relationships with the healthcare system. The choice of Klinea to participate in this initiative is a recognition of its leadership and technical capacity within the biopharmaceutical sector, which contributes significantly to the growth of this strategic sector.
Experts in Biopharmaceutical Processes
Klinea stands out in the biopharmaceutical sector for its expertise in engineering and optimization of production processes. With more than 250 projects completed, the company has proven to be a benchmark in the implementation of integral solutions ranging from design and optimization of production processes to compliance with the highest international quality standards, such as GMP and FDA.
This experience has allowed Klinea to collaborate with companies that need not only to comply with strict regulatory requirements but also to maximize the efficiency of their production processes.
According to Jordi Gibert, Head of Biotechnology at Klinea, “In biotechnology, the process is the product”. With a focus on specifying advanced technologies and a deep understanding of products and processes, Klinea ensures that each stage of production is designed to deliver the best possible results. This enables the company to deliver high-impact solutions, not only in terms of regulatory compliance but also in optimizing process performance.
Commitment to biotechnology
Participation in Biocat's Advanced Therapies Project reinforces Klinea's commitment to advancing biotechnology and developing new therapeutic solutions that can transform healthcare globally. This strategic project, which also focuses on increasing the economic and social impact of biotechnology in Catalonia, is a unique opportunity for Klinea to continue its leadership in the sector and continue to innovate in the creation of advanced therapies.
With more than 70 highly qualified professionals distributed between Barcelona, Madrid and Copenhagen, Klinea continues to add to the path of biotechnology, collaborating in initiatives that positively impact the health of thousands of people and contributing to the advancement of an ecosystem that positions Catalonia as one of the leaders in Europe and the world in the field of advanced therapies.